TGF-ß1-siRNA delivery with nanoparticles inhibits peritoneal fibrosis.
Gene Ther
; 22(4): 333-40, 2015 Apr.
Article
em En
| MEDLINE
| ID: mdl-25567535
ABSTRACT
Gene therapies may be promising for the treatment of peritoneal fibrosis (PF) in subjects undergoing peritoneal dialysis (PD). However, a method of delivery of treatment genes to the peritoneum is lacking. We attempted to develop an in vivo small interfering RNA (siRNA) delivery system with liposome-based nanoparticles (NPs) to the peritoneum to inhibit PF. Transforming growth factor (TGF)-ß1-siRNAs encapsulated in NPs (TGF-ß1-siRNAs-NPs) dissolved in PD fluid were injected into the peritoneum of mice with PF three times a week for 2 weeks. TGF-ß1-siRNAs-NPs knocked down TGF-ß1 expression significantly in the peritoneum and inhibited peritoneal thickening with fibrous changes. TGF-ß1-siRNAs-NPs also inhibited the increase of expression of α-smooth muscle actin-positive myofibroblasts. These results suggest that the TGF-ß1-siRNA delivery system with NPs described here could be an effective therapeutic option for PF in subjects undergoing PD.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
RNA Interferente Pequeno
/
Fator de Crescimento Transformador beta1
/
Nanopartículas
/
Fibrose Peritoneal
Tipo de estudo:
Prognostic_studies
Limite:
Animals
Idioma:
En
Revista:
Gene Ther
Assunto da revista:
GENETICA MEDICA
/
TERAPEUTICA
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Japão